ROCKVILLE, Md. Patients who received a dose of between 5 and 45 micrograms of an investigational flu vaccine that uses particles that mimic the influenza virus showed a “robust” immune response, according to data presented Friday at a conference in Geneva.
Novavax announced the results at the sixth annual World Health Organization Meeting on Evaluation of Pandemic Influenza Vaccines in Clinical Trials, at the WHO’s headquarters.
In the study, designed to test for safety and immunogenicity, 1,000 volunteers in Mexico ages 18 to 64 years received two doses of the so-called virus-like particle vaccine for the 2009 H1N1 flu at doses of 5, 15 or 45 micrograms. The study indicated that patients showed a protective immune response after one dose.
The company is currently enrolling subjects for a 3,000-patient second stage of the trial.